Arvinas, Inc.

ARVN Healthcare Biotechnology

Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

7.01 0.44 −5.91%
Market cap
$487.1M
P/E
57.3×
Fwd P/E
−2.7×
Dividend yield
—
F-score
5/9
Altman Z
−0.61
Beneish M
−1.60
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
ROE

+8 more TTM periods

(10.17%) (16.23%) (42.28%) 1.59%
Piotroski F-Score
4 4 3 6
ROA
(5.82%) (8.93%) (26.85%) 1.17%
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(8.52%) (14.34%) (42.53%) 1.62%
Average Days of Receivables
31.32 8.90 26.13 62.58
Free Cash Flow per Share
(4.50) (3.89) (4.01) (3.22)
Free Cash Flow
(329.50) (275.70) (256.90) (208.80)
Capital Expenditures
(2.00) (1.90) (2.80) (1.80)
Other line items
Cash ROIC
(24.36%) (24.62%) (25.64%) (18.47%)
Accounts Receivable Turnover
15.01 26.13 12.08 9.69
Accounts Payable Turnover
0.00 0.00 0.00 0.27
Inventory Turnover
— — — 0.00
Average Days of Payables
0.00 0.00 0.00 1,360.93
Days of Inventory on Hand
— — — 0.00
Tax Rate
0.00 0.00 0.00 (0.07)
Research and Development Expense of Revenue
98.43% 108.61% 284.90% 75.37%
Selling, General and Administrative Expense of Revenue
34.23% 36.52% 98.88% 27.50%
Share Based Compensation of Revenue
18.83% 16.76% 45.97% 11.59%
Operating CF/Net income
5.60 3.39 1.15 (22.26)
Depreciation/Fixed assets
(0.81) (0.63) (0.80) 0.04
Capex/Depreciation
0.45 0.58 0.64 (9.00)
Revenue per Share
4.27 3.70 1.40 4.89
Operating CF per Share
(4.47) (3.86) (3.97) (3.19)
Capex per Share
(0.03) (0.03) (0.04) (0.03)
Capex to Sales
0.01 0.01 0.03 0.01

Fold the line items

Columns are period end dates